Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity
CA 2451089 A1 · Owner: Facchiano, Antonio · Inventors: Facchiano, Angelo; Facchiano, Antonio; Facchiano, Francesco
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel peptide, derived from the human fibroblast growth factor (bFGF) is , identified. Said molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said molecule is also able to inhibit in vivo angiogenesis CD1 mice.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 19, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 19, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 19, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.